Amgen (NSDQ:AMGN) announced today that it is set to acquire Five Prime Therapeutics (NSDQ:FPRX) for approximately $1.9 billion. Thousand Oaks, Calif.-based Amgen will acquire South San Francisco-based Five Prime for $38 per share in cash, reaching the equity value of approximately $1.9 billion, according to a news release. Amgen is set to add Five Prime’s pipeline […]
Business/Financial News
Becton Dickinson acquires smart medication device maker GSL Solutions
Becton Dickinson (NYSE:BDX) announced today that it acquired smart medication device developer GSL solutions for an undisclosed amount. Franklin Lakes, N.J.-based BD said in a news release that GSL Solutions develops devices for storing and tracking controlled substances, as well as patient-specific medications that improve the security, efficiency and compliance of medication storage. Additionally, the company […]
Wearable infusion device maker Bexson Biomedical appoints SVP of drug delivery
Bexson Biomedical announced today that it appointed Sheldon Moberg as its new senior vice president of drug delivery. Santa Barbara, Calif.–based Bexson said in a news release that Moberg will lead the development of its drug delivery technologies, starting with a wearable infusion device for its BB106 therapy developed in partnership with Stevanato Group. The […]
PLx Pharma prices $63M offering
PLx Pharma (NSDQ:PLXP) announced today that it priced an underwritten public offering worth approximately $63 million. Sparta, N.J.-based PLx Pharma is offering 7.875 million shares of its common stock priced at $8 per share to the public, according to a news release. Additionally, the company granted underwriters a 30-day option to purchase up to more […]
Janux Therapeutics raises $56M Series A for T cell engager tech
Janux Therapuetics announced today that it closed a $56 million Series A financing as it develops its T cell engager technology. Avalon Ventures led the financing round, while new investors OrbiMed and RA Capital Management joined in. Additionally, existing investors Bregua and Correlation Ventures participated. OrbiMed partner Dr. Peter Thompson and RA Capital Management partner […]
Magenta Therapeutics rises on Street-beating Q4
Magenta Therapeutics (NSDQ:MGTA) shares ticked up today on fourth-quarter earnings that topped the consensus forecast. The Cambridge, Mass.-based stem cell transplantation technology developer posted losses of -$18.2 million, or -38¢ per share for the three months ended Dec. 31, 2020, marking a 21.8% bottom-line gain. Magenta’s earnings per share of -38¢ came in 3¢ ahead […]
Q BioMed wins federal contract for bone cancer drug
Q BioMed (OTCQB:QBIO) announced today that it signed an agreement for its Strontium89 drug to be included on the Federal Supply Schedule (FSS). New York-based Q BioMed’s agreement with the U.S. government provides U.S. veterans and other federal government agencies and eligible patients access to Strontium89, a treatment for metastatic bone pain related to common […]
Navidea enters into $5M private placement
Navidea Biopharmaceuticals (NYSE:NAVB) announced today that it entered into a private placement worth $5 million. Dublin, Ohio-based Navidea’s agreement comes with its largest shareholder, John K. Scott, Jr., for the purchase of $5 million in newly-designated Series E redeemable convertible preferred stock, according to a news release. Over the course of the next 18 months, the […]
Inovio Pharmaceuticals posts Street-beating Q4, touts HPV trial results
Inovio Pharmaceuticals (NSDQ:INO) shares dipped after hours today after the company presented its fourth-quarter earnings and touted clinical trial results. INO shares finished the day up 4.5% at $11.60 per share but have since dropped -2.2% after hours to $11.35 per share. The Plymouth Meeting, Pa.-based company posted losses of -$24.3 million, or -14¢ per […]
DTx Pharma completes $100M Series B
RNA-based therapeutic developer DTx Pharma announced today that it completed a $100 million Series B financing round. RA Capital Management led the financing round with participation from new investors Access Biotechnology, Surveyor Capital (a Citadel company), Cormorant Asset Management, Janus Henderson Investors, and Logos Capital. Additionally, existing investors Friedman Bioventure Fund, Eli Lilly, Viva BioInnovator […]